Kim A. Johnson

发表

Metabolism, Distribution, and Excretion of a Next Generation Selective Estrogen Receptor Modulator, Lasofoxifene, in Rats and Monkeys

C. Prakash, M. Potchoiba, Kim A. Johnson, 2008, Drug Metabolism and Disposition.

“DMD #21808” 1 METABOLISM, DISTRIBUTION AND EXCRETION OF A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, LASOFOXIFENE, IN RATS AND MONKEYS

C. Prakash, Kim A. Johnson, C. Schroeder, 2008 .

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

C. Prakash, Kim A. Johnson, 2005, Drug Metabolism and Disposition.

Metabolism, Pharmacokinetics and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High Resolution LC-MS/MS

C. Prakash, D. Dalvie, M. Potchoiba, 2008 .

CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Li

C. Prakash, T. O’Connell, Kim A. Johnson, 2008, Drug Metabolism and Disposition.

Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.

C. Prakash, Ajit K. Shah, Kim A. Johnson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance

C. Prakash, D. Dalvie, M. Potchoiba, 2008, Drug Metabolism and Disposition.

Nuclear Magnetic Resonance Spectroscopy for the Study of Drug Metabolism

Stella Huang, Y. Shu, M. Reily, 2012 .

Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia.

M. Seager, J. Macor, A. Hendricson, 2017, Bioorganic & medicinal chemistry.

DMD#7765 METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

C. Prakash, B. Lum, A. Rakhit, 2005 .

7765 METABOLISM AND EXCRETION OF ERLOTINIB , A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE , IN HEALTHY MALE VOLUNTEERS

C. Prakash, B. Lum, A. Rakhit, 2005 .

Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.

L. Hamann, N. Meanwell, Tao Wang, 2016, Bioorganic & medicinal chemistry letters.

Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

J. Macor, Shuang Liu, T. Molski, 2014, ACS medicinal chemistry letters.

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

C. Prakash, B. Lum, A. Rakhit, 2006, Drug Metabolism and Disposition.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248.

Michael Sinz, Dawn Parker, Kim A Johnson, 2013, Journal of medicinal chemistry.

Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects

C. Prakash, M. Gardner, Kim A. Johnson, 2008, Drug Metabolism and Disposition.

A Robust Methodology for Rapid Structure Determination of Microgram‐Level Drug Metabolites by NMR Spectroscopy

Stella Huang, Y. Shu, Kim A. Johnson, 2012 .

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

3-{ [ 4-TERT-BUTYL-BENZYL )-( PYRIDINE-3-SULFONYL )-AMINO ]-METHYL }-PHENOXY )-ACETIC ACID , AN EP 2 RECEPTOR-SELECTIVE PROSTAGLANDIN E 2 AGONIST , IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

C. Prakash, Kim A. Johnson, 2005 .

ACETIC ACID , AN EP-2 RECEPTOR SELECTIVE PGE 2 AGONIST , IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

C. Prakash, Kim A. Johnson, 2005 .

METABOLISM, EXCRETION AND PHARMACOKINETICS OF (3-{[4- ACETIC ACID, AN EP-2 RECEPTOR SELECTIVE PGE2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS BIOTRANSFORMATION OF A PYRIDINYL SULFONAMIDE ANALOG

C. Prakash, Kim A. Johnson, 2005 .

Rapid structure determination of microgram-level drug metabolites using HPLC-MS, fraction collection and NMR spectroscopy

W. Humphreys, Stella Huang, Y. Shu, 2010 .

Antitumor efficacy of a thrombospondin 1 mimetic CovX-body.

Lingna Li, G. Woodnutt, N. Levin, 2011, Translational oncology.

Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.

C. Prakash, Ajit K. Shah, Kim A. Johnson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

C. Prakash, D. Dalvie, M. Potchoiba, 2008, Drug Metabolism and Disposition.